



## Tandem Diabetes Care Announces Upcoming Conference Participation

July 31, 2025

SAN DIEGO--(BUSINESS WIRE)--Jul. 31, 2025-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will host meetings and present a company update at the following investor conferences:

- Canaccord Genuity 45<sup>th</sup> Annual Growth Conference on Tuesday, August 12, 2025 at 1:00pm Eastern Time (10:00am Pacific Time), and
- Morgan Stanley 23<sup>rd</sup> Annual Global Healthcare Conference on Wednesday, September 10, 2025 at 9:15am Eastern Time (6:15am Pacific Time).

In addition, the Company will host meetings at the Bernstein Insights: Healthcare Leaders and Disruptors 2<sup>nd</sup> Annual Healthcare Forum on Wednesday, September 24, 2025.

The presentations will be webcast live, and an archive recording will be available for 30 days. The link to the live webcasts and archive will be accessible on Tandem Diabetes Care's Investor Center website located at <http://investor.tandemdiabetes.com> in the "Events & Presentations" section.

### About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company's pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit [tandemdiabetes.com](http://tandemdiabetes.com).

Tandem Diabetes Care, the Tandem logo, Control-IQ+, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250731552590/en/): <https://www.businesswire.com/news/home/20250731552590/en/>

### Media Contact:

858-366-6900

[media@tandemdiabetes.com](mailto:media@tandemdiabetes.com)

### Investor Contact:

858-366-6900

[IR@tandemdiabetes.com](mailto:IR@tandemdiabetes.com)

Source: Tandem Diabetes Care, Inc.